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Abstract | Pregnancy is a complex and vulnerable period that presents a number of challenges to 22 
women, including the development of postpartum psychiatric disorders (PPDs). These disorders 23 
can include postpartum depression and anxiety, which are relatively common, and the rare but 24 
more severe postpartum psychosis. In addition, other PPDs can include obsessive–compulsive 25 
disorder, post-traumatic stress disorder and eating disorders. The aetiology of PPDs is a complex 26 
interaction of psychological, social and biological factors, in addition to genetic and environmental 27 
factors. The goals of treating postpartum mental illness are reducing maternal symptoms and 28 
supporting maternal-child and family functioning. Women and their families should receive 29 
psychoeducation about the illness, including evidence-based discussions on risks and benefits of 30 
each treatment option. Developing effective strategies in global settings that allow the delivery of 31 
targeted therapies to women with different clinical phenotypes and severities of PPD is essential. 32 
 2 
[H1] Introduction  33 
Pregnancy and the first year after childbirth (which collectively can be referred to as the perinatal 34 
period) is arguably one of the most transformative times in a woman’s life. This timeframe is also a 35 
complex and vulnerable period that presents a number of challenges for women. In particular, an 36 
increased risk for onset or worsening of psychiatric illness including mood disorders, anxiety 37 
disorders and psychosis exists during the first three months postpartum. All types of psychiatric 38 
disorders can occur during the postpartum period, with many chronic disorders starting before 39 
pregnancy and persisting throughout pregnancy into the postpartum period1. In this Primer, we 40 
focus specifically on the postpartum psychiatric disorders (PPDs). Collectively, the postpartum 41 
psychiatric disorders (PPDs) can include postpartum depression, which is relatively common; 42 
common anxiety disorders such as generalized anxiety disorder (GAD; which can include anxieties 43 
about the health of the baby); post-traumatic stress disorder (PTSD; which can occur due to a 44 
traumatic childbirth experience or can reflect pre-existing symptoms due to previous traumas 45 
before conception or during pregnancy); and the rarer, but usually severe presentation of 46 
postpartum psychosis. Other PPDs include eating disorders (which can worsen or recur 47 
postpartum, particularly when the infant is undergoing weaning), and obsessive–compulsive 48 
disorder (OCD).  49 
In pregnancy, depressive and anxiety disorders are common with recent population estimates of 50 
11% for depressive disorders and 15% for anxiety disorders.2 Further, antenatal anxiety and 51 
depression are one of the greatest risk factors for postpartum psychiatric disorders (PPD).3 52 
Inadequate social support and a history of adverse life events increases the risk for PPDs in all 53 
countries and levels of society4, 5. However, this risk is increased in poorer socioeconomic 54 
populations and lower income countries, due to poverty and limited access to health care.6 55 
In recent years, awareness of the potentially serious adverse consequences in both the mother 56 
and the baby associated with untreated perinatal psychiatric illness has increased. Maternal 57 
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suicide due to postpartum mood disorders (including unipolar and bipolar depressive disorders) is 58 
a leading cause of maternal mortality. 7, 8,9 In addition, perinatal mood disorders are associated with 59 
an increased risk for low birth weight and premature birth, impaired mother-infant attachment, and 60 
infant malnutrition during the first year of life10, 11.  61 
In this Primer, we focus on maternal PPDs, as they are common, morbid, and have a growing 62 
literature on the underlying pathophysiology. These disorders should not be confused with the so-63 
called ’baby blues’, which are usually described as transient mild mood and anxiety symptoms that 64 
often persist ≤2 weeks and usually resolve spontaneously with no sequelae.12 If the symptoms of 65 
the ‘baby blues’ worsen and/or persist, they are considered PPDs. Herein we discuss the 66 
epidemiology of PPDs, and their underlying mechanisms and pathophysiology. We mainly focus on 67 
maternal PPDs, although paternal disorders are mentioned in some instances (Box 1). Importantly, 68 
we review the latest evidence on diagnosis, screening and prevention as well as management of 69 
PPDs. Lastly, we hope to put in context the public health impact of these disorders on mothers, 70 
their children and families to encourage wide scale adoption of strategies that make maternal 71 
mental health a global priority13.  72 
 73 
[H1] Epidemiology  74 
Data on the incidence of postpartum depression are from studies conducted in countries across 75 
the world, and variable incidence and prevalence are reported between countries14. By 76 
comparison, studies estimating the incidence and prevalence of postpartum psychosis are 77 
primarily carried out in Europe15, and demonstrate less variability in reported incidence and 78 
prevalence16, 17. Several methodological factors have influenced these differences. 18 For example, 79 
particularly for postpartum depression, the definition of the postpartum period is variable between 80 
studies, and has been defined as up to 4 weeks, 3 months, 6 months or 12 months postpartum19. 81 
Differences in study designs, such as using different tools to define case-groups and phenotypes 82 
can lead to variability in the reported number of cases. Data sources for postpartum depression 83 
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and postpartum psychosis include self-reports and interviews, in addition to some population-84 
based register data16. Moreover, the incomplete availability of longitudinal data that is needed to 85 
distinguish between first-time and recurrent psychiatric episodes might impede calculations of the 86 
true incidence and prevalence of PPDs. Consequently, a variation in reported incidence and 87 
prevalence could be explained by differences in methodologies between studies, which make 88 
direct comparisons difficult. In addition, the diverse symptoms of PPDs pose specific challenges to 89 
the estimation of prevalence and incidence of these disorders20.  90 
As the literature surrounding the epidemiology of PPDs continues to grow with well-designed 91 
studies, we will have a better understanding of if differences in the incidence and prevalence of 92 
postpartum depression and postpartum psychosis are due to local/regional and national 93 
differences, or if the differences are due to variable study designs and data sources. This 94 
knowledge will assist hypothesis generating that might provide clues for the aetiology of these 95 
disorders. 96 
 97 
[H2] Mood disorders and anxiety  98 
Postpartum depression, comprising major depressive disorder and subthreshold depression, has 99 
an estimated point prevalence of 13% in high-income countries11, and ~20% in low-income and 100 
middle-income countries, 3 months postpartum (Box 2)21. In women with a history of any eating 101 
disorder, the prevalence of postpartum depression has been estimated at 35%22. Studies of 102 
postpartum depression often rely on self-reported questionnaires, including the commonly used 103 
Edinburgh Postnatal Depression Scale (EPDS)14, 23.  104 
Although the prevalence estimates for postpartum mood disorders ranges between studies, 105 
guidelines are available that state that these disorders pose substantial public health risks and 106 
consequently, must be identified and treated24,25. Moreover, there is consensus that childbirth is a 107 
strong and potent risk factor for bipolar disorder. Indeed, the risk of underlying bipolarity in first-108 
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onset depression that occurs in the postpartum period is higher than in first-onset depression that 109 
occurs outside the perinatal period. In addition, women with bipolar disorder have a high risk of 110 
postpartum episodes, including depression, anxiety, mania and psychosis 26, 27. 111 
The estimated prevalence of postpartum anxiety disorders is ~10%, with a prevalence of 6% for 112 
GAD 28. Anxiety disorders have substantial comorbidity with postpartum depression and other 113 
disorders, including postpartum PTSD, eating disorders and the exacerbation of personality 114 
disorders17.  115 
 116 
 [H2] Postpartum psychosis  117 
The onset of a severe mental disorder requiring acute inpatient psychiatric treatment in the first 118 
postpartum months is ~1 per 1,000 births29-32, and are considered some of the most severe forms 119 
of illness in psychiatry 18. These severe psychiatric disorders that have an onset in the immediate 120 
postpartum period are often called postpartum psychosis, which is an umbrella term for disorders 121 
recorded as, for example, mania, mixed episodes, psychotic depression, or psychosis not 122 
otherwise specified33. Women with bipolar disorder have the highest risk for postpartum psychosis 123 
than women with other psychiatric diagnosis, as the risk for postpartum relapse in women with 124 
bipolar disorder is on average 37%18. However, variations also occur within bipolar disorder, as the 125 
risk of a severe episode (ie postpartum psychosis) is greater for women with bipolar I disorder than 126 
women with bipolar II disorder34. Additionally, the risk of symptom recurrence is particularly high for 127 
women with bipolar disorder who are not receiving medication during pregnancy18 .  128 
Relapse of psychosis can also occur in women with other psychiatric disorders, such as women 129 
with schizophrenia, although this is less common35 (~16% within the first 12 months postpartum), 130 
and manifests differently from what is observed in women with bipolar disorder16.  131 
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Despite the widespread use of the term postpartum psychosis, this diagnosis is not recognized in 132 
current classification systems, including both ICD-10 and DSM-5 36. However, it is clear that 133 
psychotic episodes are more prevalent during the postpartum period than in other periods in a 134 
woman’s life, and evidence clearly suggests a particular vulnerability in women with bipolar 135 
disorder 29. 136 
In women with severe postpartum psychiatric illness, maternal suicide is often a predominate 137 
concern. Although maternal suicide is a leading cause of maternal mortality7, the rates of 138 
completed suicide in postpartum women are lower than those in age-matched women without 139 
children37. Nonetheless, the prevention of maternal suicide is paramount and requires careful 140 
monitoring during the postpartum period and possibly extending beyond the first year. For 141 
example, one study demonstrated that most postpartum suicides occurred between 9 and 12 142 
months postpartum and that the perinatal suicides were by highly lethal means (such as via 143 
firearm), suggesting that limiting follow-up to 1, 3 or 6 months postpartum might be insufficient.38 144 
 145 
[H1] Mechanisms/pathophysiology  146 
As previously mentioned, childbirth is one of the most potent triggers of psychiatric illness. Given 147 
that postpartum mental health disorders are one of the few occurrences in psychiatry whereby a 148 
biological trigger occurs at a known time point, elucidating the pathophysiology of these disorders 149 
might shed light on the mechanisms of mood and psychiatric disorders more broadly, and is vital 150 
for developing new treatment approaches. 151 
The aetiology of all psychiatric disorders, including PPDs, is a complex interaction of psychological, 152 
social and biological factors, including the effect of genetic and environmental influences on risk 153 
(Figure 1)12. The involvement of particular combinations of aetiological factors differs between 154 
specific PPDs34; for example, biological factors might have a greater role in the triggering of 155 
postpartum psychosis, whereas psychosocial factors might have an important contribution in 156 
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postpartum depression.34 These are areas of intense investigation and future research is needed to 157 
extend our understanding of the many ways that psychological and biological processes interface. 158 
Stopping or changing medications in women with a prior history of psychiatric disorders due to 159 
concerns about the safety of medication during pregnancy could be considered a simple 160 
explanation for the triggering of PPDs. However, continuing medication in pregnancy is protective 161 
against mood disorders in a subset of patients39. Similarly, discontinuation of medication does not 162 
guarantee that a woman will relapse40. However, there is much that is still not understood about 163 
PPDs and the onset of PPDs reflects the outcome of many different pathways that manifest in 164 
vulnerable women. Future research will need to disentangle the mechanisms of depression in 165 
women before, during and after pregnancy to increase our understanding of the similarities and 166 
differences between perinatal depression and depression occurring at other times in life. We will 167 
next discuss current theories on psychosocial and biological contributions that increase risk for 168 
PPDs.  169 
 170 
[H2] Psychosocial factors and comorbidities  171 
Psychological and social stressors contribute to the development of maternal PPDs and are 197 
associated with poorer outcomes in the infants or children41, 42. In particular, adverse life events 198 
and a history of trauma have a greater prevalence in women that develop postpartum mood 199 
disorders, compared with mood disorders outside of the perinatal period 4, 43, 44. A history of 200 
adverse early life experiences can substantially affect a mother’s ability to have a strong 201 
attachment with her infant45, and adverse parent–infant interactions and worse attachment are 202 
associated with development of PPDs 46-48.  203 
Social support has a vital role in either contributing to or mitigating the impact of postpartum mood 204 
disorders on both the mother and child49. Indeed, social support, or the degree of tangible support 205 
provided from the social network of the mother and from the partner (such as financial support or 206 
 8 
assisting with infant care), have the greatest effects on postpartum depression 50.  207 
 208 
Other psychosocial risk factors include a past history of a mood disorder, which is consistently 209 
associated with an increased risk of postpartum depression and postpartum psychosis34. In 210 
addition, although the strength of the association between risk factors and PPDs is variable 211 
between high-income countries and low-income and middle-income countries, one of the strongest 212 
psychosocial risk factors in both settings is domestic violence and previous abuse, including abuse 213 
during childhood. 4, 51 Other risk factors with a medium to strong association with PPDs include 214 
marital difficulties, migration status and antenatal depression or anxiety17, 52. In addition, poverty, 215 
young age (between 14 and 21 years of age), substance misuse, increased parity, multiple births, 216 
an unwanted pregnancy, neuroticism, pregnancy complications including obesity and comorbidities 217 
(for example diabetes, hypertension and pre-eclampia) and neonatal problems are associated with 218 
PPDs17. 219 
 220 
 [H2] Genetic factors 221 
Data from twin and adoption studies have implicated genetic factors in the aetiology of psychiatric 222 
disorders outside of the perinatal period, including schizophrenia and mood disorders53, 54. 223 
However, only recently have genetic investigations, primarily of postpartum depression and 224 
postpartum psychosis, been conducted. 225 
Genetic epidemiological and linkage studies for postpartum depression have demonstrated the 226 
involvement of genetic factors 55, 56, 57 and two studies have demonstrated the increased heritability 227 
of postpartum depression compared with depression outside of the perinatal period58, 59. To date, 228 
studies have suggested that episodes of postpartum psychosis are a marker for a more-familial 229 
form of bipolar disorder and that the puerperal triggering of bipolar illness is familial. 60, 61. However, 230 
a genome-wide association study (GWAS) for either postpartum depression or postpartum 231 
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psychosis using modern genomics methods has not yet been carried out. Future genetic studies of 232 
postpartum mood disorders using modern genomics methods will require international 233 
collaborations and consortia to include large number of patients; these studies are currently 234 
underway62, 63.  235 
Psychological stressors and early life adverse events have a lasting negative impact and can result 236 
in pathophysiological changes and altered gene expression due to increased allostatic load (the 237 
cumulative stress on the body that is a sum of lifetime exposure to stress)64. Potential mechanisms 238 
underlying how stressful life events change gene expression include epigenetic modification (such 239 
as DNA methylation and histone modification that change DNA accessibility and chromatin 240 
structure, subsequently regulating gene expression)65, changes in transcriptional control of stress-241 
responsive pathways66, and shortened telomere length67, 68 . Epigenetic alterations have been 242 
reported in two genes, HP1BP3 and TTC9B, which have different methylation patterns in women 243 
with postpartum depression, depending on whether the mood symptoms begin during pregnancy 244 
and continue into the postpartum period, compared with symptoms that develop postpartum only 69, 245 
70. These data indicate that different gene patterns might arise based on the timing of symptom 246 
onset. However, given the history of non-replication in many genetic studies, these findings require 247 
replication and overall, the mechanism of action in postpartum depression remains to be 248 
established.  249 
 250 
 [H2] Sleep Disruption 251 
An almost universal feature of pregnancy and childbirth is disruption to sleep. In addition, sleep 252 
and circadian rhythm disruption can trigger the onset of psychiatric disorders, particularly episodes 253 
of mania in the postpartum period71, 72. Thus, that circadian rhythm disruption has not received 254 
more attention as a potential mechanism in PPDs is surprising. 255 
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Numerous studies have demonstrated profound changes in maternal sleep patterns during the 256 
perinatal period. Pregnant women experience poorer subjective sleep quality, increased waking, 257 
and more sleep-wake transitions than women who are not pregnant73. In the postpartum period, 258 
new mothers have frequent night waking, decreased night-time sleep, increased daytime napping, 259 
and a more irregular sleep-wake schedule, which is speculated to increase the risk of PPDs74. The 260 
mechanisms underlying the reported disrupted maternal sleep patterns in the perinatal period have 261 
been reported in two cross-sectional studies. The first study demonstrated a blunted melatonin 262 
amplitude is in postpartum women, compared with non-pregnant women,75 and the second study 263 
demonstrated differences in circadian rhythms between perinatal women with depression and 264 
perinatal women without depression; indeed, in the second study, women with depression had 265 
clinically-significant circadian rhythm phase shifts.74 Further research is needed to better 266 
understand the mechanisms of sleep disruption that might trigger PPDs and potential interventions 267 
that target the circadian rhythm disruptions during the perinatal period76.  268 
 269 
[H2] Reproductive Hormones 270 
One important hypothesis for the aetiology of PPDs is based on the temporal onset of these 271 
disorders immediately after childbirth, which is a time of major physiological change for women, 272 
including alterations in hormonal systems. Multiple lines of evidence have demonstrated that 273 
fluctuations in reproductive hormones (such as oestrogen and progesterone) during the perinatal 274 
period are substantial contributors to the development of postpartum mood disorders in vulnerable 275 
women. Gonadal steroid hormones (such as oestrogen and progesterone) are produced at very 276 
high levels during pregnancy, but rapidly decrease to pre-pregnancy levels after childbirth. One 277 
study simulated this pattern of hormone expression and demonstrated substantial mood symptoms 278 
(such as sadness, anhedonia and anxiety) during the withdrawal period in five of eight women with 279 
a history of postpartum depression, but in none of the eight women with no history of postpartum 280 
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depression77. Thus, women who are vulnerable to postpartum psychiatric episodes might not have 281 
gross abnormalities in endocrine physiology (such as no differences in the absolute levels of 282 
hormones), but might have an abnormal response to the hormonal fluctuations of pregnancy and 283 
childbirth.  284 
Reproductive hormones have important functions in the central nervous system. Oestrogen and 285 
progesterone receptors are expressed throughout the brain and can modulate neurotransmission 286 
and neuroplasticity via both genomic and non-genomic mechanisms. For example, rodent studies 287 
have shown that ovariectomy reduces and estradiol administration increases brain-derived 288 
neurotrophic factor (BDNF) levels in the hippocampus and the forebrain78; BDNF levels are 289 
decreased by stress and depressive symptoms and are increased following treatment with 290 
antidepressants79. The rapid fall in oestrogen levels in the postpartum period might, therefore, 291 
reduce BDNF levels and increase susceptibility to PPDs in women who are vulnerable. Similarly, 292 
progesterone has an important role in regulating neurotransmitter synthesis, release and transport 293 
80 and, has been shown to up-regulate BDNF expression in the hippocampus and cerebral cortex 294 
in rodent models81.  295 
The neurosteroid, allopregnanolone, which is a major metabolite of progesterone, might also have 296 
an important role in the aetiology and, potentially, in the treatment of postpartum depression82, 83. 297 
Allopregnolone is a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors84, 298 
85 and animal models have demonstrated that intravenous allopregnolone administration 299 
significantly reduces anxiety and depressive symptoms86. Allopregnanolone concentrations reach 300 
peak physiological levels during the third trimester of pregnancy and rapidly decrease following 301 
childbirth87, 88. The failure of GABAA receptors to adapt to the rapid fluctuations in allopregnanolone 302 
levels [Au:OK?] at childbirth is hypothesized to be a trigger for postpartum depression89, 90. This 303 
line of inquiry is being further explored by the development of brexanolone (a proprietary 304 
formulation of allopregnanolone) as a treatment for postpartum depression91,92.  305 
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Oxytocin is a neuroactive hormone that supports childbirth, lactation, maternal behavior, and social 306 
bonding93. Some studies have demonstrated an inverse association between circulating oxytocin 307 
levels and postpartum depression94 although other studies have not found this95 .The alterations in 308 
the oxytocin system that occur during pregnancy and childbirth do not occur in isolation, and the 309 
role of oxytocin in postpartum depression is likely to be complex and not accounted for by absolute 310 
levels, similar to the roles of other neuroactive hormones 83. 311 
Further, recent neuroimaging data increases our understanding of the neurobiological basis 312 
underlying perinatal mood disorders and the development of maternal behavior. Indeed, one study 313 
demonstrated that the effects of a polymorphism in BDNF (BDNF Val66Met) on hippocampal 314 
function are selectively modulated by estradiol96. This work lends further data to the importance of 315 
the role of sex steroids on the regulation of behavioural functions associated with psychiatric 316 
disorders, such as emotional processing, arousal, cognition, and motivation. Thus, it follows the 317 
involvement of sex steroids of brain function could be revealed using neuroimaging. Indeed, 318 
multiple cortical and subcortical brain regions have altered activity observed using functional MRI 319 
or PET (such as, measurement of brain MAO-A97) in mothers with depression, in response to infant 320 
and non-infant emotional cues98, 99. These alterations might impact important neuronal networks 321 
that are associated with learned reward, reaction to stimuli, stress, motivation and executive 322 
functioning. In addition, recent research from functional MRI studies shows distinct neurobiological 323 
patterns that distinguish anxiety and depression occurring in the perinatal period, compared with 324 
other times of a woman’s life, and these patterns might have significant impact on the mother-325 
infant relationship100.  326 
 327 
[H2] Other factors  328 
[H3] Stress axis. The postpartum period is a time of great flux for the HPA stress axis101. Indeed, 329 
alterations in the hypothalamic–pituitary–adrenal (HPA) axis occur during pregnancy, such as 330 
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corticotropin-releasing hormone (CRH) production by the placenta, resulting in significantly 331 
increased levels during pregnancy, which abruptly decline postpartum102, and rising levels of 332 
gonadal steroids that contribute to puerperal hypertrophy of the pituitary and adrenal glands, 333 
leading to increases in ACTH and cortisol levels103. CRH fluctuations during the perinatal period 334 
might trigger HPA axis dysregulation and contribute to the onset of depressive and anxiety 335 
symptoms in a subset of vulnerable women 104; however, inconsistent findings have been 336 
reported105, 106.  337 
 338 
[H3] Thyroid hormones. Thyroid hormones have been implicated in the development of 339 
postpartum mood disorders. Thyroid binding globulin (TBG, which transports thyroid hormones in 340 
the blood) concentrations increase during pregnancy and might be an index of sensitivity to 341 
elevated oestrogen levels. Some data also suggest that decreased TBG levels are a predictor of 342 
perinatal depression107. In addition, first-onset postpartum autoimmune thyroid disorders often co-343 
occur with postpartum mood disorders 108. The occurrence of both disorders coincides with the 344 
postpartum rebound phenomena of the maternal immune system, suggesting an overlap in 345 
aetiology109. Supporting this hypothesis, women with increased thyroid peroxidase antibodies 346 
during pregnancy have an increased risk for postpartum psychiatric episodes109, 110. Accordingly, 347 
the assessment of thyroid function (such as measurement of thyroid-stimulating hormone levels, 348 
tri-iodothyronine (T3) and tetraiodothyronine (T4)) is an essential part of diagnostic evaluations in 349 
women with postpartum psychiatric episodes.  350 
 351 
[H3] Neuroimmune pathways. Neuroimmune pathways might also have a role in the 352 
pathophysiology of postpartum mood disorders101, 111-113. The transition from pregnancy into the 353 
postpartum period is characterized by an accelerated immune response (mediated through both 354 
pro-inflammatory and anti-inflammatory mediators for healing and involution) during labor that 355 
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continues into the early postpartum period 114. Consequently, immune changes at the end of 356 
pregnancy might predict postpartum depression. IL-6 levels are increased in women with 357 
postpartum depression compared with postpartum women who do not have depression in some, 358 
but not all studies. 112,115 However, leptin (a protein hormone made by adipose cells that regulates 359 
energy and has inflammatory functions), might also be associated with postpartum depression. 360 
Indeed, decreased maternal serum leptin levels during delivery are associated with a higher risk for 361 
postpartum depression, and might potentially serve as a biomarker for postpartum depression115. 362 
Lower levels of Clara cell protein (CC16, an endogenous anti-inflammatory compound) are 363 
associated with PPD a few weeks later116, 117. Furthermore, decreased levels of ω3 364 
polyunsaturated fatty acids (PUFAs) at the end of the third trimester are suggested to associate 365 
with increased risk of PPD in the early postpartum period118. The underlying mechanism is 366 
hypothesized to be increased peripheral inflammation118 owing to the anti-inflammatory effects of 367 
ω3 PUFAs. In summary, dysregulation of the crosstalk between the immune system and the HPA-368 
stress axis is hypothesized to be associated with the onset of postpartum depression101, 119  369 
Interestingly, first pregnancies are more often followed by psychiatric episodes than subsequent 370 
pregnancies, which may illustrate the dysregulation of psychoneuroimmune systems. This effect is 371 
hypothesized to be due to the biological differences between first and subsequent pregnancies, 372 
and has raised the possibility of an aetiological link with other medical conditions that have a 373 
similar increase in prevalence in first pregnancies such as pre-eclampsia120. Intriguingly, pre-374 
eclampsia and postpartum psychosis are both associated with immune dysregulation, for example 375 
the increased rates of postpartum autoimmune thyroiditis108, 109 and alterations in immune 376 
biomarkers (such as, CNS autoantibodies) in women with postpartum psychosis121. In addition, 377 
abnormalities in monocyte and T cell function and tryptophan breakdown has been demonstrated 378 
in patients with postpartum psychosis or mania, compared with postpartum women without any 379 
psychiatric symptoms.122 Patients with postpartum psychosis had monocytosis and failed to 380 
demonstrate the physiological T cell increase that is normally observed during the postpartum 381 
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period. These findings support the notion that immune system dysregulation contributes to 382 
affective instability and severe postpartum episodes122.  383 
Future studies are needed to extend our understanding of the ways in which psychological and 384 
biological processes interact in PPDs. For example, social support might exert a stress-buffering 385 
effect via the downregulation of stress responses, including inflammatory reactivity to stressors and 386 
dampened sympathetic and hypothalamic-pituitary-adrenal (HPA) axis activity 123, 124.  387 
 388 
[H1] Diagnosis, Screening and Prevention  389 
As with all psychiatric disorders, the diagnosis of postpartum depression is reached by a 390 
comprehensive clinical interview and diagnostic criteria that provide an operationalised definition of 391 
the disorder, using classification systems such as the Diagnostic and Statistical Manual of Mental 392 
Disorders, Fifth Edition (DSM-5)125 or International Classification of Diseases, Tenth Edition 393 
(ICD10)126. Diagnostic criteria are similar across the DSM-5 and ICD-10, which are the two most 394 
common classification systems; however, the DSM-5 uses the term ‘depression with peripartum 395 
onset’ to refer to the onset of depression during pregnancy and into the first month postpartum, 396 
whereas ICD10 does not use a primary code referring to the perinatal period, although a second 397 
code denoting postpartum onset is available (which is not used in practice). However, the 398 
diagnosis of psychiatric disorders is more than a list of symptoms and the impact on symptoms of 399 
functioning; diagnosis should also include an understanding of predisposing aetiological factors, 400 
triggers and maintenance factors, which are elicited by a comprehensive biopsychosocial 401 
assessment24. 402 
Postpartum depression is one of the most common postpartum psychiatric disorders, and can be 403 
mild and relatively self-limiting lasting only a few weeks, or can be more severe, with severe 404 
episodes potentially including psychotic symptoms17. Some symptoms of depression such as 405 
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fatigue, sleep disturbance and appetite disturbance need careful enquiry, as a woman with a baby 406 
will be more tired than usual and have disrupted sleep (due to the baby needing a feed), although 407 
appetite might not be affected as breastfeeding will stimulate appetite despite a low mood. 408 
Checking whether the mother is able to sleep when the baby is asleep, whether the fatigue persists 409 
after rest and the interest in food will help establish whether the symptoms are pathological and if 410 
they are indicative of postpartum depression. Notably, anxiety might be a prominent symptom in 411 
postpartum depression63, or can be a symptom of a comorbid anxiety disorder127. Diagnostic 412 
assessment should evaluate a history of manic or hypomanic symptoms, as first-onset postpartum 413 
depression can indicate underlying bipolar disorder26. Diagnostic challenges include barriers to 414 
disclosing symptoms due to stigma128 and variations in the manifestation of symptoms, which might 415 
reflect cultural or educational differences129. In addition, it is important to ensure symptoms are not 416 
due to an underlying medical condition such as thyroid disease or an early presentation of first 417 
episode psychosis.  418 
Although postpartum psychosis is not included as a primary diagnosis in the DSM-5 or ICD-10, this 419 
disorder is still recognised clinically and is usually considered to be a severe mood disorder.16 420 
Women with postpartum psychosis often have a history of bipolar disorder.16 Most women have 421 
prodromal symptoms before the overt onset of postpartum psychosis; however, some women have 422 
acute onset of severe symptoms 130, 131. Evaluation of women with postpartum psychosis includes 423 
assessment of manic, depressed, anxious and psychotic symptoms, and the assessment of the 424 
risk of causing harm to herself or her baby. Women with postpartum psychosis can present with 425 
either low or high mood (both elation and irritability), or frequently can present with a mixed state, 426 
including symptoms of both mania and depression; a minority of women have an atypical symptom 427 
profile with disorientation and/or disturbance of consciousness 132. Symptoms can also manifest as 428 
delusions, hallucinations, and particularly confusion and perplexity and patients can also have 429 
severe mood swings, insomnia, agitation and rapid deterioration. Postpartum psychosis is usually 430 
a rapid onset severe psychosis, typically starting within the first 2-4 weeks after birth, and is 431 
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considered a psychiatric emergency as a lack of self-care and an inability to care for the infant can 432 
lead to suicide and/or, in rare cases, infanticide16. Accordingly, assessment should be carried out 433 
quickly (for example, The National Institute for Health and Care Excellence (NICE) recommend 434 
assessment within 4 hours of clinical presentation; in clinical practice this means within 24 hours of 435 
the acute onset of severe psychiatric symptoms) to ensure the woman can be cared for safely and 436 
appropriately. Excluding other medical disorders, such as cerebral space occupying lesions, 437 
thyroid disorders or infections is important as part of the diagnostic work-up. In many cases the 438 
mother’s partner or family ask for psychiatric evaluation when the mother is irritated or agitated and 439 
not aware that she is seriously ill. 440 
 441 
Anxiety disorders (such as GAD and panic disorder), OCD and PTSD can all manifest in the 442 
postpartum period. OCD is characterised obsessive thoughts. Obsessions are intrusive, repetitive 443 
thoughts, images or impulses that are unacceptable and/or unwanted and give rise to subjective 444 
resistance. By contrast, delusions that occur in psychotic disorders are fixed, false beliefs133 that 445 
need appropriate psychological intervention17. Postpartum OCD poses a particular diagnostic 446 
challenge, as intrusive thoughts about harm befalling the infant (such as, what if I drop my infant or 447 
I accidently cut the infant with a knife when I’m cooking) might be perceived as delusional and 448 
could lead to concerns about the safety of the infant. However, these thoughts are not associated 449 
with actual direct harm and the obsessions remain very ego-dystonic and highly distressing to the 450 
patient. Traumatic childbirth experiences can trigger PTSD, particularly in women with prior 451 
histories of trauma134. Differentiating the exacerbation of PTSD symptoms in women with past 452 
trauma and new onset PTSD owing to traumatic childbirth is important135. Past trauma history 453 
should include assessment of prior childhood abuse, adult interpersonal or other violence, among 454 
other forms of trauma. In addition, many women with PTSD or OCD present with symptoms of 455 
anxiety and mood symptoms, making the diagnosis of any one particular disorder a challenge63, 136.  456 
 457 
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Women with a previous history of psychiatric disorders will often experience a worsening of 458 
symptoms during the postpartum period, although few studies have examined strategies to 459 
mitigate this exacerbation of symptoms39. For women without a prior history of psychiatric 460 
disorders, the acute onset of psychiatric symptoms in the postpartum period is often highly 461 
distressing. However, whether the first onset of psychiatric symptoms in the postpartum period 462 
indicates the beginning of a more persistent and chronic mood disorder, or is a condition that will 463 
be restricted only to the postpartum period is unclear. This is an important area for future study.  464 
 465 
[H2] Screening  466 
Screening for postpartum depression has attracted widespread interest from researchers, clinicians 467 
and policy makers due to the high prevalence and associated sequelae in terms of maternal 468 
morbidity and adverse child outcomes. In many countries, screening for postpartum depression 469 
during routine obstetrical care, including care by health visitors, is inconsistent, and this strategy 470 
has become an area of focus in many countries. In addition, up to 60% of perinatal women with 471 
depression do not seek help 137. However, given the availability of screening instruments and 472 
effective treatments 138, Clinical Practice Guidelines and recommendations are increasingly 473 
supportive of routine screening139, 140. More generally, international guidelines reflect a consensus 474 
that improved identification of PPDs [Au:OK?] is vitally important 141,142. Accordingly, several 475 
national campaign to increase awareness of PPDs are underway, such as the Maternal Mental 476 
Health Alliance143 in the UK. This alliance is a coalition of organizations that are dedicated to 477 
achieving consistent, accessible and quality mental health care in the first year after giving birth. In 478 
addition, state mandates for perinatal depression screening are increasing in the United States, 479 
including the US Preventive Services Task Force recommendation140. However, although this task 480 
force has concluded that the evidence base that is sufficient to recommend screening for perinatal 481 
 19 
depression when combined with adequate support systems25, 140 this conclusion has also been 482 
criticised by others144.  483 
The most widely researched and used screening tool for postpartum depression is the brief 10-item 484 
Edinburgh Postnatal Depression Scale (EPDS145), which was designed to exclude symptoms that 485 
can be normal features of the perinatal period, such as poor sleep, but that are often included in 486 
other self-report measures. A cut-off score of 13 is most commonly used to recommend further 487 
diagnostic assessment146, 147. In addition, the EPDS includes question about thoughts of self-harm, 488 
which can help to mobilise risk assessment and can predict suicidal intent148. The EPDS has been 489 
used prenatally and validated in a number of languages, its properties are relatively well-490 
understood 147 and it appears to be highly acceptable in the target population 149,150. High EPDS 491 
scores can reflect several psychiatric diagnoses. For example, among the 826 screen-positive 492 
women out of a sample of 10,000 women, the most common primary diagnosis was unipolar 493 
depressive disorder (found in 68.5% of women), but almost two-thirds of women had co-morbid 494 
anxiety disorder and 22.6% had a bipolar disorder 151. These data highlight another potential 495 
benefit of the EPDS: that most women with a false-negative result for unipolar depression have 496 
another diagnosable, and potentially treatable, psychiatric condition. 497 
Other generic or perinatal-specific depression measures have been used to identify perinatal 498 
depression, but are not as well validated in perinatal women as the EPDS. Other measures include 499 
the Postpartum Depression Screening Scale152, the Beck Depression Inventory-II153 and the 500 
Patient Health Questionnaire-9154,155. Alternatively, two case finding questions (the so-called 501 
Whooley questions 141, 156, 157) can be asked to women to determine whether further mental health 502 
assessment should be carried out, and the use of these questions is recommended by NICE 503 
guidelines in the United Kingdom. The Whooley questions can also be used to detect any 504 
psychiatric disorder, and are not limited to depression2. 505 
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As previously mentioned, postpartum depression are frequently co-morbid with anxiety (in 4.3% of 506 
women [Au:OK?] ). As anxiety substantially impacts maternal functioning and fetal and infant 507 
development28, 158 159, this has spurred efforts to screen for postpartum anxiety. Three sub-items of 508 
the EPDS (the so-called EPDS-3A) can be used to identify perinatal anxiety disorders and sub-509 
syndromal anxiety160. Other screening instruments for anxiety disorders include the Perinatal 510 
Anxiety Screening Scale (PASS)161 and the generalized anxiety disorder scale (GAD-7)162. 511 
Screening tools for perinatal OCD and PTSD are also available, such as the specific perinatal OCD 512 
screening scale (The POCS),163 and a short screening scale for PTSD (SPAN), respectively.164.  513 
The utility of routine screening for postpartum psychosis, hypomanic and manic symptoms and 514 
bipolar disorder faces several barriers including a lack of evidence base of effectiveness and the 515 
reduced predictive value of screening for a relatively rare condition. Despite steady progress in this 516 
area165, 166 a consensus test with well-known precision and an agreed cut-off has not been 517 
identified167,168. However, the Mood Disorder Questionnaire (MDQ) has shown solid psychometric 518 
properties for assessing bipolar disorder and is increasingly used 169. Taking a full personal and 519 
family history might help to identify vulnerability to bipolar disorders which could trigger further 520 
diagnostic assessment, given the strong association between bipolar disorder and increased risk 521 
for PPDs141, 142.  522 
In general, screening programs in the postpartum period should include a clear pathway from 523 
screening, to diagnostic assessment and treatment170. Best practice guidelines agree that all 524 
women who have a positive screen need subsequent assessment, during which, co-morbidities 525 
and the woman’s wider psychosocial context can be explored. Currently, only such well-resourced, 526 
integrated management programs have provided evidence that perinatal mental health is improved 527 
by depression screening 171, 172. In this regard, e-screening and e-treatments to facilitate integrated, 528 
cost-effective care might be useful173. Few well-understood, validated screening approaches for 529 
PPDs that can ultimately improve morbidity and mortality are available. Indeed, further building of 530 
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the evidence-base for screening, including the cost-effectiveness of perinatal depression screening 531 
as a policy direction is required142, 174. 532 
 533 
[H2] Prevention  534 
Interventions for the prevention of postpartum depression or postpartum anxiety are intended to 535 
prevent the onset, duration, or recurrence of these disorders. Prevention can reduce the mental 536 
health, physical health and socio-economic burden associated with postpartum depression for 537 
mothers, their offspring and families, as well as for health systems. The effectiveness of prevention 538 
of postpartum depression is facilitated by the fact that pregnant women are motivated to address 539 
factors that will affect their baby175. The assessment of risk factors for PPDs helps with diagnosis 540 
and formulation, but is also important for identifying potentially modifiable targets for prevention 541 
and treatment (Box 3)176. Thus, it is a requirement for both symptom screening and risk 542 
assessment that systems exist for adequate follow-up and support. Furthermore, women and 543 
clinicians should be informed that the established risk factors might have limited predictive value 544 
for individual patients and, therefore, do not guarantee which women will develop or not develop 545 
postpartum depression.  546 
Some psychosocial and psychological interventions have reduced the risk of women developing 547 
postpartum depression, although no single intervention type or modality appears superior to 548 
others. Data from trials included in a Cochrane review176 as well as randomized controlled trials 549 
included in a qualitative review,175 point towards particularly positive impacts when interventions 550 
target at-risk groups (such as women with a previous episode of depression or a recent life 551 
stressor), or include interpersonal therapy (IPT). As relationship challenges and lack of social 552 
support constitute strong risk factor for PPD, the interpersonal focus of the IPT intervention, 553 
therefore aims to address this causative or aggravating factor. Interventions with the most promise 554 
include interventions targeting at-risk groups (such as women with a previous episode of 555 
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depression or a recent life stressor). Trials included in these reviews were conducted among high 556 
risk women, based on various factors, as well as women enrolled from the general perinatal 557 
population. 558 
Trials assessing the use of interpersonal therapy, cognitive behavioural therapy, peer support, 559 
parental preparedness, and person-centred approaches for prevention of postpartum depression 560 
have demonstrated significantly positive results, whereas trials assessing the use of cognitive 561 
behavioural therapy for postpartum depression have demonstrated mixed results. These results, 562 
disaggregated for universal, selective or indicated prevention strategies are summarized in a more 563 
recent systematic review and meta-analysis177. The interventions were delivered using several 564 
modalities, including home visits and telephone support, provision by professional and lay 565 
practitioners, individual and group-based sessions, through multiple contact sessions and at 566 
postpartum initiation176.  567 
There is conflicting evidence for the treatment of vulnerable women with antidepressants for the 568 
prevention of depressive episodes or anxiety symptoms during the perinatal period as well as 569 
anxiety symptoms has conflicting evidence 178. One of the earliest studies demonstrated a 570 
reduction in recurrence of postpartum major depression with prophylactic antidepressant treatment 571 
179. Small but emerging literature has suggested hormonal therapies, light therapy and other forms 572 
of circadian manipulation might be promising therapies for prevention of depression180. There is no 573 
strong evidence for the use of hormonal therapies, acupuncture, supplementation with omega-3 574 
polyunsaturated fatty acids, light therapy and other forms of circadian manipulation for prevention 575 
of postpartum depression. 177,180  576 
Interventions for the prevention of postpartum psychosis include careful monitoring for symptom 577 
development in women at high risk and adjustments of prophylactic medication, especially in 578 
women with bipolar disorder18, 24. Prophylactic treatment during pregnancy might reduce the rate of 579 
postpartum relapse in women with bipolar disorder, although no evidence from randomized 580 
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controlled trials for this is available. For women with previous postpartum psychosis, prophylactic 581 
treatment with lithium or antipsychotics immediately postpartum might reduce relapse18.  582 
  583 
[H1] Management  584 
The goals of treating mental illness in the postpartum period are to reduce maternal psychiatric 585 
symptoms and to support maternal-child and family functioning. All women and their families 586 
should receive education about the illness and the potential treatment options, including the 587 
potential benefits and harms of each treatment option. Social support should be optimized and 588 
physical and psychiatric comorbidities should be addressed. In addition, strategies to assist women 589 
in obtaining sleep and a stable circadian rhythm are helpful, given that sleep deprivation is 590 
common during the postpartum period. In many cases, the symptoms of PPDs influence maternal–591 
child interactions, which should be observed and discussed in a non-judgmental way.  592 
Although specific recommended treatments depend on the underlying diagnosis, in general, a 593 
stepped care approach is advocated, in which the intensity of the intervention matches the severity 594 
and acuity of the clinical presentation. For example, women with mild symptoms of depressive, 595 
anxiety, obsessive–compulsive and/or trauma or stressor-related disorders should first be offered 596 
the lowest-intensity interventions such as peer support and guided self-help, whereas women who 597 
do not respond to these treatments might require formal psychotherapeutic interventions, such as 598 
psychological therapies. For women with severe symptoms, who do not respond to non-599 
pharmacological treatment, or who have bipolar disorder or psychosis, pharmacological 600 
interventions are likely to be introduced as a first-line treatment, used alone or in combination with 601 
a lower-intensity intervention. In such cases, the well-established benefits of breastfeeding on the 602 
infant must be considered in the context of maternal mental wellbeing, the passage of psychotropic 603 
medication into breast-milk and the infant, and the potential effects of medications on the neonate. 604 
Indeed, when breast-feeding is challenging, and/or when frequent nighttime feedings leads to 605 
sleep disruption, symptoms of depression or anxiety might be precipitated or exacerbated. In these 606 
 24 
cases, the benefits of breastfeeding must be weighed against the risk of ongoing maternal mental 607 
illness, and formula feeding is a viable and often recommended alternative. Other somatic 608 
treatments, such as electroconvulsive therapy (ECT), can be considered in women with treatment-609 
refractory disorders. Throughout, monitoring progress to determine when or if to move to a higher-610 
intensity intervention, and to ensure safety for mother and child is important. In the initial 611 
assessment and during treatment the patient and her family should be asked if thoughts of suicide 612 
or infanticide have occurred. Safety concerns and/or evidence of active psychosis are medical 613 
emergencies that require specialist consultation, emergency hospitalization and treatment. 614 
 615 
[H2] Mood disorders and anxiety  616 
Treatment of postpartum depression and other non-psychotic mental disorders (such as anxiety, 617 
OCD and trauma and stressor-related disorders; Box 4) depends on the severity of the initial 618 
presentation and the level of functional impairment, including the effect on the maternal–child 619 
interaction.128 For women with a past history of mental illness, the previous treatment response and 620 
the time to response of previous episodes should be considered. The patient’s treatment 621 
preference, in addition to as access to care and utilization of care should also be considered in all 622 
women, as patients who receive their preferred treatment are most likely to benefit from this 623 
treatment than other treatments.181 Most women with non-psychotic mental disorders often prefer 624 
psychotherapy over pharmacological treatments, although the uptake and effectiveness of this 625 
therapy can be limited due to barriers in attending appointments, such as unpredictable infant 626 
schedules and competing childcare responsibilities.182 Similarly, fathers also prefer psychological 627 
treatments to pharmacological therapy.183 However, some women prefer pharmacological 628 
treatment alone, so individualizing treatments based on patient preferences is important. Treating 629 
maternal postpartum depression might not always improve the maternal–infant relationship, and 630 
additional interventions aimed at the mother–infant dyad or the family as a whole might be 631 
required.184  632 
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 633 
[H3] Psychological Interventions. Most trials for postpartum depression have focused on non-634 
pharmacological treatments. For women with mild postpartum depression, psychosocial treatments 635 
including peer support, guided self-help, and supportive counseling by trained professions such as 636 
public health nurses (at home, or in support groups) can improve symptoms. For example, one 637 
systematic review of 5 trials demonstrated a 1 year remission rate of 68% in women with 638 
postpartum depression who received psychosocial treatments compared with a remission rate of 639 
54% in women treated with standard primary care.185 For women with moderate symptoms of 640 
depression, or women who do not responded to psychosocial strategies, psychotherapies such as 641 
cognitive-behaviour therapy (CBT) and interpersonal therapy (IPT) that specifically address the 642 
psychological and related challenges of transitioning to parenthood are effective when delivered in 643 
individual, group, and partner-assisted formats, and either in-person, by telephone, or online.186 A 644 
systematic review of 4 CBT and 1 IPT trials demonstrated a pooled remission rate of 60.3% for 645 
these interventions, compared with a rate of 48.1% for usual care.185  646 
 647 
In addition, a CBT-based program was demonstrated to reduce worry and depressive symptoms in 648 
women with postpartum anxiety disorders, including GAD, social phobia and OCD, compared with 649 
symptoms at baseline.187 The effectiveness of CBT for postnatal OCD symptoms was confirmed in 650 
a small RCT.188. Although additional research is required, CBT-based interventions for postpartum 651 
anxiety disorders, and specifically interventions such as eye movement desensitization and 652 
reprocessing (EMDR) and trauma-focused CBT for trauma and stressor related disorders, can be 653 
used, although the latter two interventions have not been specifically evaluated in postpartum 654 
women189.  655 
The increasing use of internet-based CBT and the development of mobile apps that use this 656 
treatment modality demonstrates the power of digital health, which is often more accessible than 657 
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traditional psychotherapy, and extends to individuals who can’t participate in psychotherapy. A 658 
good example of this is MumMoodBooster, which was developed in Australia173.  659 
 660 
[H3] Drug therapies. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and 661 
serotonin norepinephrine reuptake inhibitors (SNRIs) are the mainstay of pharmacological 662 
treatment for postpartum anxiety and depressive disorders. These therapies can be used alone or 663 
in combination with psychosocial or psychological treatments. In a systematic review, the pooled 664 
remission rate was significantly higher in patients receiving SSRIs (46.0%) compared with those 665 
receiving placebo (25.7%).190 Although pharmacological therapies can be used alone or in 666 
combination with psychosocial or psychological treatments, whether combinatorial therapy is 667 
superior to either one alone has not been evaluated in postpartum women. However, combinatorial 668 
treatment does not lead to further improvements in functional outcomes compared with medication 669 
alone, in non-perinatal populations.191, 192 To our knowledge, there are no drug treatment trials in 670 
maternal anxiety disorders, or in paternal postpartum depression or anxiety. However, SSRI and 671 
SNRI medications are first line pharmacological treatments for anxiety and depression outside the 672 
postpartum period. The duration of antidepressant therapy required for new-onset postpartum 673 
depression, anxiety or a related disorder has not been studied, but clinicians are recommended to 674 
follow guidelines for these disorders in the general population. For depression, the initial treatment 675 
should be continued for 6 months to 1 year after remission; longer durations are required for 676 
severe and/or recurrent illness.193 677 
  678 
Many women and their partners are concerned about the safety of using antidepressant drugs 679 
during breastfeeding. However, the use of antidepressants during the postpartum period is not a 680 
contraindication to breastfeeding, and indeed, the avoidance of medication when needed for 681 
severe illness is associated with maternal suicides194. The passage of SSRIs and SNRIs into 682 
breast-milk is variable between drugs, but most pass into the breast-milk at <10% of the maternal 683 
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dose, which is compatible with breast-feeding.195 As such, changing the antidepressant drug or the 684 
dose during the perinatal period to switch to a drug with lower breast-milk passage is generally not 685 
recommended. For new-onset postpartum depression, sertraline is often recommended as a first-686 
line pharmacological treatment due to very minimal passage into breast-milk (Figure 2). However, 687 
in patients with a prior history of psychiatric disorders, therapies that have previously demonstrated 688 
efficacy should be considered, even those that have less data regarding safety during 689 
breastfeeding. Other SSRIs, SNRIs or mirtazapine (an atypical antidepressant) also have minimal 690 
passage into breast-milk, so these drugs are unlikely to be a cause for concern. Buproprion is 691 
generally not given to lactating women due to case reports of infant seizures associated with 692 
exposure to this drug.196 In cases of severe depression and/or anxiety (with or without psychotic 693 
features), older antidepressants, other therapies such as benzodiazepines or antipsychotics might 694 
be indicated.  695 
 696 
[H3] Other treatments. Given the likely role of hormonal fluctuations in the aetiology of postpartum 697 
depression, hormonal treatments have been evaluated. Transdermal oestrogen therapy reduced 698 
the symptoms of postpartum depression in one small study, but further trial are required. Progestin 699 
therapy worsens postpartum depressive symptoms.197 One trial of demonstrated the superiority of 700 
allopregnenalone to placebo in improving depressive symptoms in 21 women with severe 701 
postpartum depression,92 although this requires further investigation. Complementary and 702 
alternative medicine treatments (for example, folate, s-adenosylmethionine, massage and 703 
acupuncture) are not well-supported by evidence.198 However, using aerobic exercise for 704 
postpartum depression was recently examined in a systematic review and has good supporting 705 
evidence for mild symptomatology 199. ECT can be considered in severe or treatment-refractory 706 
cases of depression. 707 
 708 
[H2] Postpartum psychosis  709 
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Fluctuations in symptoms are common in women with postpartum psychosis, and thoughts of 710 
infanticide or suicide are often well hidden. Thus, outpatient treatment is not safe and psychiatric 711 
hospitalization is recommended for diagnostic evaluation and treatment 15. The preferred treatment 712 
setting is a mother–baby joint admission unit, but these units are not available worldwide 200, 201. 713 
Alternatives are the admission of the mother only to a hospital with expertise in perinatal 714 
psychiatric care or women’s mental health, or, if these facilities are unavailable, admission to a 715 
standard mental health inpatient setting, or based on a careful assessment of the safety of both the 716 
mother and the infant, intensive home treatment where available and with appropriate 717 
supervision16. The effect of these approaches on long term outcomes of the mother and baby are 718 
being investigated15.  719 
The management of postpartum psychosis is dependent on psychiatric history. For women with 720 
known severe psychiatric illness with non-perinatal episodes, reviewing the nature and 721 
effectiveness of past treatments and restarting previous effective treatment is important. 722 
Management of women without a history of bipolar disorder or other severe psychiatric disorder are 723 
summarized in Figure 2. The main treatment goals for women without a prior history of bipolar 724 
disorder, psychosis or other severe psychiatric disorder [Au:OK?] include the limitation of the 725 
current episode and the prevention of a bipolar disease course with multiple episodes. Accordingly, 726 
management in the first year postpartum should focus on full recovery (that is, complete symptom 727 
remission and social and vocational functioning). In the absence of guidelines and controlled trials, 728 
treatment recommendations are based on results from naturalistic cohort studies and expert 729 
consensus groups24, 202. The largest study (consisting of 68 patients) demonstrated the efficacy of a 730 
stepwise sequence of short-term benzodiazepines, antipsychotics and lithium, and showed high 731 
remission rates (remission in 98.4% of women) in the acute phase 203. Moreover, this study 732 
demonstrated that lithium monotherapy is protective against relapse of psychosis, depression and 733 
mania [Au:OK?] within one year. The second largest study described successful ECT treatment in 734 
34 patients with postpartum psychosis of whom many had symptoms of catatonia204. The 735 
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effectiveness of lithium and ECT is supported by case reports 205. Successful treatment with 736 
antipsychotics has been described in case reports 206, 207, but antipsychotic monotherapy did not 737 
show efficacy in a cohort study 203. Together, lithium monotherapy might be the preferred initial 738 
intervention for postpartum psychosis but adjunctive treatment with benzodiazepines or 739 
antipsychotics is useful for the acute treatment of agitation, mania and psychotic symptoms, given 740 
the well documented effectiveness in non-perinatal populations. Several antipsychotics are used 741 
for the treatment of severe PPDs including risperidone, quetiapine and olanzapine208. ECT is the 742 
primary treatment for patients with severe catatonic or depressed psychotic features, or if patient’s 743 
prefer this therapy 15.  744 
Anticonvulsants (that is, antiepileptic medications) are also used less frequently as mood 745 
stabilizers in the treatment of bipolar disorder because of concerns of teratogenicity. However, 746 
valproate use during pregnancy and lactation is associated with neural tube defects and 747 
neurocognitive developmental delays in the offspring24, 209. Thus, valproate use is not advised 748 
during the perinatal period, unless the risk/benefit assessment determines a prior efficacy in 749 
particular women. By contrast, lamotrigine is used for the treatment of bipolar–depression (not 750 
bipolar–mania) and is not associated with an increased risk of congenital malformations in 751 
offspring. 210. A review of recent studies demonstrated that lamotrigine had no adverse outcomes 752 
on infant IQ or neurodevelopment.211  753 
The management of a breastfeeding woman with a severe psychiatric episode is challenging 754 
due to concerns about the exposure of breastmilk to pharmacological therapies and the need 755 
for sleep preservation in the mother15. The use of lactation inhibitors should be avoided. In some 756 
countries, the mother is recommended to breastfeed only if extensive psychiatric support and 757 
access to a pediatric professional that can monitor the infant are available. Moreover, the mother 758 
and her partner should be educated about the risks of breastfeeding with pharmacotherapy. In 759 
other countries, a more individualized approach (for example, NICE guidelines) based on previous 760 
responses to medication, preferences regarding breastfeeding and psychopathology24, other than 761 
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avoidance of breastfeeding if lithium (rather than an antipsychotic) is used. Small case series have 762 
provided information regarding the safety of lithium in lactation212, 213. When possible, level of 763 
lithium in the infants serum should be closely monitored; on average, the serum level of lithium is 764 
25% of the maternal levels, but the range can vary and dehydration can lead to toxic levels 15,213. 765 
No adverse effects were reported in ten infants of breastfeeding mothers who received ECT204. 766 
 767 
[H1] Quality of life  768 
The symptoms and morbidity of postpartum depression are often reported in the academic 769 
literature, but this offers only a rather constricted view of the quality of life (QOL) of women with 770 
PPDs. 125,214, 215 Nevertheless, the classic core symptoms of a depressive disorder would be 771 
expected to decrease the subjective quality of both an individual’s inner life experience (anhedonia, 772 
sadness, hopelessness, thoughts of death), and their functioning (psychomotor retardation or 773 
agitation, disturbed sleep). Anxiety is frequently co-morbid and this further influences quality of life 774 
with persistent worry symptoms. 775 
 Definitions vary, but QoL is a broader multidimensional construct which commonly incorporates 776 
two central aspects: emotional well-being (including, frequency and intensity of joy, sadness, 777 
affection) and life evaluation (how satisfied one is with one’s life, for example, housing, 778 
employment). Health, and the ability to function, as an essential component of QoL is referred to as 779 
health-related quality of life (HRQoL). Maternal QoL during the postpartum period also affects her 780 
infant’s current and future quality of life. Many mothers with postpartum depression have difficulty 781 
interacting with their infants in a positive way216, such as making less eye contact, showing less 782 
synchronous responsiveness, being uninvolved and showing restricted affect during mother-infant 783 
interactions.217-219 Infant attachment security is a key predictor of child outcomes, including 784 
neurological, psychological and social outcomes over the course of development220. In addition, 785 
children of mothers with perinatal depression might have poorer psychological outcomes when 786 
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they reach 18 years of age221. Some women have an intrusive engagement style that might lead to 787 
long-term difficulties in child social, cognitive and behavioural domains222. Women with postpartum 788 
psychosis face even more many parenting challenges often including disrupted attachment, which 789 
impact on the quality of life for mother and child.223  790 
One of the most widely used generic measures of QOL is the 36 item short-form (SF-36)224, 225, 791 
which has eight health domains that measure limitations in physical or usual role activities due to 792 
health issues, limitations in usual role or social activities due to emotional issues, pain, mental 793 
health, vitality, and general health perceptions. The SF-36 has been used in over 1,000 794 
publications and for over 130 disorders including those that occur during the postpartum period, 795 
and both the full and short versions of this scale have been validated by numerous studies225, 226. 796 
However, few measures of QOL have been developed specifically for use in the postpartum 797 
period227 . Only 228 three instruments for use during the postpartum period were reported in one 798 
systematic review: The Mother-Generated Index (MGI)229, the Maternal Postpartum Quality of Life 799 
Questionnaire (MAPP-QOL)230 and the Rural Postpartum QOL scale (RPQoL)231. The MGI requires 800 
women to specify domains of their life that have been affected by the birth of their baby, either 801 
positive or negative, and to then score these out of 10. 232 The most common changes reported 802 
were tiredness, less personal time, less time with partner or other family members, a worse 803 
relationship with partner or other family members, physical complaints, low self-esteem, financial 804 
worries, negative feelings towards the baby, more housework, poor sex life, pleasure from baby, a 805 
sense of happiness or fulfilment, contentment as family, high self-esteem and good social life229.  806 
Not surprisingly, people with depressive illness in general report lower scores on generic QoL and 807 
HRQoL measures, as do women experiencing postpartum depressed mood. 233, 234 Small studies in 808 
postpartum women also suggest QoL is amenable to intervention. Improvements in QOL are not 809 
fully explained by improvements in the severity of depressive symptom suggesting that 810 
interventions should go beyond the mere reduction of symptom severity and consider other factors 811 
that contribute to QoL as targets for intervention. Maternal-specific measures of QOL could be 812 
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integrated into postpartum depression screening programs or routine postnatal care235, 236. Indeed, 813 
QoL measures that allow a women to identify which areas of her life are most important to her, 814 
could be used to allow women to indicate where she would like to see improvements.229 Emerging 815 
studies have highlighted the beneficial effect of social support on QOL237, in addition to risk factors 816 
for reduced QOL such as younger age and lower socio-economic status in women with postpartum 817 
depression 238. 818 
PPDs have economic considerations and can affect quality-adjusted life years (QALY)142. QALY 819 
takes into account how treatment affects quality and quantity of life, and accordingly, QoL 820 
measurement is necessary for studies of cost-effectiveness of treatments. Compelling data from 821 
the London School of Economics239 demonstrated the high economic costs of PPDs and the need 822 
to address the loss of QALYs of women and their children, by treatment and prevention of these 823 
disorders. This finding is particularly pertinent given the short and long-term effects of postpartum 824 
depression. Indeed, as most women recover from postpartum mood disorders, these disorders can 825 
become chronic in a subgroup of women240. One study demonstrated that, for each one-year 826 
cohort of births, perinatal depression, anxiety and psychosis cost the UK around £8.1 billion in the 827 
long-term.239 828 
 829 
[H1] Outlook  830 
The postpartum period is a vulnerable time for onset of psychiatric illness. Indeed, postpartum 831 
mood and anxiety are heterogeneous and might be triggered by biopsychosocial factors including 832 
a vulnerability to the robust endocrine and immune-related changes that occur at childbirth. The 833 
heterogeneity of these disorders requires a thoughtful approach to assessment and treatment 834 
planning that includes the clinical presentation, family and personal psychiatric history, other 835 
psychosocial risk factors (including history of trauma), and awareness of potential biological or 836 
genetic contributions that might influence risk and vulnerability.  837 
 33 
The precise vulnerability that leads to some women developing PPDs is currently unknown and 838 
novel research approaches are needed to identify the underlying pathophysiology of both 839 
prepartum and postpartum anxiety, depression and psychosis. This will require a multi-faceted 840 
approach in preclinical, clinical and translational research, to determine the mechanisms behind 841 
the neurobiology and physiological correlates of PPDs, and the observed peripartum mood and 842 
mothering behaviors. Additionally, these strategies must address the differences in the timing of 843 
symptom onset and the diverse types of symptoms.  844 
Given the morbidity and mortality of postpartum psychosis, episodes of psychosis might be best 845 
considered to represent women with a bipolar disorder diathesis with a puerperal trigger. 846 
Understanding this trigger will be beneficial and should allow the development of new treatments 847 
and, ultimately, enable the prevention of psychosis or prevent unfavourable outcomes in women at 848 
high risk. Effective evidence based treatment approaches are available for psychosis and 849 
depression, including psychopharmacology, psychotherapy and ECT and circadian manipulation. 850 
However, postpartum depression and postpartum psychosis require different and targeted 851 
treatment approaches and therefore, bipolarity must be considered in the evaluation and 852 
management of all women with postpartum mood and anxiety disorders. In addition, primary 853 
treatment goals should include the limitation of the current episode and the prevention of future 854 
episodes (including unipolar or bipolar disease with multiple episodes, and chronic anxiety). 855 
Whether there a continuum of severity between postpartum depression and postpartum psychosis, 856 
or whether these disorders represent different conditions with different aetiological factors requires 857 
further study. 858 
A potential barrier to the engagement and retention of women in the treatment of postpartum mood 859 
disorders is stigma. Understand this stigma and the fear that women have regarding postpartum 860 
mood disorders is essential. The voices of women with postpartum mood disorders must be 861 
incorporated into the development of services to ensure the needs of women, their infants and 862 
families are met241, 242.  863 
 34 
To date, the amount of research provides an important road map for PPDs in general, and 864 
guidelines for screening or identification and treatment for perinatal depression in many countries 865 
gives a strong mandate to improve mental health care for all women in the perinatal period. Thus, 866 
developing effective strategies in low, middle and high income countries that allow the delivery of 867 
targeted therapies to women with different clinical phenotypes and severity of PPDs is imperative. 868 
In addition, whether the current ICD-10 and DSM-5 classification systems are adequate for 869 
detecting specific phenotypes or diagnostic groups of patients should be evaluated. We should 870 
also consider that PPDs might be phenotypically different than psychiatric disorders that begin 871 
during pregnancy. Indeed, disorders that occur postpartum might have unique characteristics in 872 
epidemiology, pathophysiology, psychosocial contributions, prevention and management than 873 
disorders that occur during pregnancy. 874 
In summary, PPDs are morbid and costly disorders. Advocating for early identification and 875 
screening that begins in pregnancy to identify women at risk, in addition to timely and effective 876 
treatments of PPDs is essential. Given the recent advances in knowledge, this an incredibly 877 
exciting time for research in perinatal mood disorders. New approaches might allow the 878 
identification of the underlying causes of postpartum mood disorders, which could lead efforts to 879 
identify women at risk and personalize treatment. Although genetic, biological and hormonal 880 
signals likely have an important role in risk of these disorders, psychosocial contributions including 881 
the current impact of lifetime stressors must be part of comprehensive work-up and treatment plan. 882 
The social determinants of postpartum mood disorders, such as poverty, domestic violence, poor 883 
housing, and insecure migrant status, should also be assessed as part of routine practice of 884 
maternal health care for all women. Finally, we must recognize that maternal mental health is 885 
necessary for the physical and mental health of mothers, infants and families17 and advocating and 886 
protecting this population is our obligation.  887 
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Display items 1539 
 1540 
Box 1. Paternal postpartum depression. 1541 
Fathers can also experience depression after the birth of a child. Indeed, in men, the prevalence of 1542 
depression after the birth of a child is greater than at other times during life243. Although the 1543 
literature of paternal depression is much smaller than that for maternal depression, the available 1544 
literature demonstrates that paternal depression increases the risk for long-term adverse outcomes 1545 
in the child due to potential impairments in parenting244, 245. In addition, a strong link between 1546 
maternal depression and paternal depression has been reported. Pregnant women who had 1547 
partners with depression during their pregnancy had worse depression symptom severity during 1548 
the first six months postpartum246. Thus, including fathers in health assessments during the 1549 
postpartum period and screening fathers for postpartum psychiatric disorders at similar time 1550 
intervals as maternal screening is important. Efforts aiming to improve the overall health and 1551 
functioning of the family unit will lead to best outcomes for the child243, 245. 1552 
 1553 
 1554 
  1555 
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Box 2. Postpartum mental illness in low-income and middle-income countries  1556 
In resource-poor settings, women of reproductive age typically have socio-economic and health 1557 
challenges that interplay in mutually reinforcing ways.247, 248 For example, low levels of education, 1558 
low gender status, food insecurity, domestic abuse and lack of access to social and health services 1559 
leave women and girls vulnerable to maternal mortality and chronic morbidities, including common 1560 
mental health disorders.249, 250 Indeed, the prevalence of common perinatal mental disorders in low- 1561 
and lower-middle-income countries is higher than in high-income countries. One systematic review 1562 
and meta-analysis21 demonstrated a weighted mean prevalence of 15.6% in pregnant women and 1563 
19.8% in women after childbirth. The most strongly associated factors for perinatal mental 1564 
disorders are socio-economic disadvantage, unintended pregnancy, younger age, unmarried 1565 
status, lacking intimate partner empathy and support, hostile inlaws, partner violence, insufficient 1566 
emotional and practical support, a history of mental health problems and in certain settings, a 1567 
female infant. 21 1568 
 1569 
[H1] Considerations for management 1570 
Mental health prevention and treatment investments in high-income countries is more than US$50 1571 
per year per person, compared with less than US$2 in most LMIC,251 resulting in a profound 1572 
paucity of mental health providers in these settings. The intervention coverage for common mental 1573 
disorders (including those that occur during the perinatal period) ranges from 7% to 28% in 1574 
LMICs.252 The low monetary allocation represents, in part, poor appreciation by decision makers of 1575 
the effect of mental illness on population disability and socio-economic development, low levels of 1576 
political will and capacity, and competing health and development priorities.253 Interventions that 1577 
are most likely to succeed in LMICs would, therefore, need to adopt a systems strengthening, 1578 
integrated and low-cost approach. Examples showing promise have integrated mental health into 1579 
primary care, maternal and child health services or into the routine community based delivery of 1580 
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health services (carried out by trained lay workers, or primary care healthworkers, using a task-1581 
sharing approach)254. Emerging evidence supports the benefit of including poverty alleviation 1582 
strategies in to mental health interventions.255  1583 
 1584 
[H1] Types of interventions 1585 
A systematic review and meta-analysis of evidence of common perinatal mental disorder trials from 1586 
LMIC, reported similar relative risk outcomes in studies carried out in high-income countries256. For 1587 
the 13 trials selected, the pooled effect size for maternal depression was −0.38. In this review, 1588 
trials that demonstrated positive results used several culturally adapted treatment paradigms, 1589 
either singly or in combination. The Thinking Health Program in Pakistan was a cognitive behaviour 1590 
therapy (CBT) intervention delivered in homes in a semi-rural setting by Lady Health Workers. 257 1591 
Uptake of the intervention leveraged the belief, within multi-generational households, that the 1592 
intervention with the mother would improve the infant’s well-being . In an urban, deprived setting in 1593 
Chile, midwives and nurses were trained to deliver eight weekly structured psychoeducational 1594 
group sessions. These sessions included information about symptoms and treatments, some 1595 
problem solving strategies, behavioural activation strategies (such as scheduling pleasurable 1596 
activities) and some cognitive techniques using postnatal examples 258 .  1597 
Subsequently, a trial in Zimbabwe 259 used peer counsellors to deliver six weeks of group problem 1598 
solving therapy adapted for the local setting to postnatal women with depression. In this study, 1599 
family members were co-opted to support the mothers through strategies identified in the problem 1600 
solving and a specific treatment element that explored community resources and support systems 1601 
was included. Six weeks after the intervention, the drop in mean EPDS score was greater in the 1602 
PST group than the control group who received antidepressant therapy. No difference in outcomes 1603 
between women with or without HIV was reported. 1604 
 1605 
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Box 3. Targeting risk factors for postpartum depression. 1606 
Assessing the common psychosocial risk factors for postpartum depression might have the 1607 
following functions: 1608 
• Assisting in the initiation of targeted interventions or determining rational management 1609 
decisions to mitigate the risks across several global settings through  1610 
o risk reduction interventions (for example, referring women for social grants, to 1611 
domestic violence support groups or to a women’s shelter and provision of 1612 
integrated interventions for the mood disorder, which also addresses domestic 1613 
violence 260 1614 
o activation of protective factors, (such as interpersonal therapy for relationship 1615 
difficulties or activating social support networks)175, 260. 1616 
• Assisting in screening of women who have an increased risk of postpartum depression but 1617 
do not currently have the disorder. 1618 
• Assisting in timely referral for support in women with suspected postpartum depression and 1619 
complicated psychosocial risk factors who are reluctant to endorse symptoms during 1620 
screening due to stigma and poor contextual validity of the screening tool in some global 1621 
settings, among other reasons261. This approach acknowledges that there may be several 1622 
contextual factors contributing to false negative mental health screening results. 1623 
 1624 
  1625 
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Box 4. General management guidelines for non-psychotic psychiatric disorders  1626 
1. Identify somatic comorbidities and optimize their management.  1627 
2. Check the mode of delivery, if complications were present and if delivery was experienced 1628 
as traumatic. In the case of post-traumatic stress symptoms, consider specific treatments. 1629 
3. Assess for suicidal thoughts and intrusive thoughts of harm toward the baby. Consider the 1630 
safety of the baby and whether the mother can provide care for the baby if she is alone or if 1631 
other adult supervision is required.  1632 
4. Ask the mother of her attitude towards her baby and observe maternal-child interactions. 1633 
Consider specific treatments with signs of problematic interactions or bonding. 1634 
5. Review the feeding pattern of the baby. Address problems with breast or bottle-feeding. 1635 
6. Provide strategies to preserve sleep, such as finding another person to feed the infant at 1636 
night. 1637 
7. Assess psychiatric history before delivery. Review the nature and effectiveness of past 1638 
treatments, and restart previous effective treatment when appropriate. 1639 
 1640 
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  1642 
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Figure 1, Mechanisms of postpartum psychiatric disorders.  1643 
Several factors have been implicated in the aetiology of postpartum psychiatric disorders, including 1644 
both postpartum depression and postpartum psychosis. These factors include psycho-social 1645 
factors and biological factors that are specific to pregnancy and the postpartum period, such as 1646 
drastic alterations in gonadal sex steroids and impaired mother-infant interactions. Whether the 1647 
aetiology of psychiatric disorders occurring in prenatally, during pregnancy or during the 1648 
postpartum period is different requires future study.  1649 
 1650 
Figure 2. Management of first onset postpartum psychiatric disorders. 1651 
Management of postpartum psychiatric disorders should take into account the diagnosis (such as 1652 
psychosis, anxiety or depression), symptom severity and, with regards to mood and anxiety 1653 
disorders, whether the mother is breastfeeding.  1654 
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